The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
Official Title: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
Study ID: NCT04998786
Brief Summary: This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relapse . The patient population will consist of adult men and women more than 70 years, who meet eligibility criteria. Following the screening period, patients will be enrolled and treated then, they will receive therapy with Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression.
Detailed Description:
Minimum Age: 70 Years
Eligible Ages: OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
CHR, Annecy, , France
CH de la cote basque, Bayonne, , France
CHRU Hopital Haut Lévêque, Bordeaux, , France
CHU de Brest, Brest, , France
CHU, Caen, , France
CHU, Clermont-Ferrand, , France
CHRU, Dijon, , France
CHD les Oudairies, La Roche-sur-Yon, , France
CHRU Lille, Lille, , France
CHU, Limoges, , France
CH Lyon Sud, Lyon, , France
CHRU, Nancy, , France
CHU, Nantes, , France
Hopital de l'archet, Nice, , France
CHU Henri Mondor, Paris, , France
Hopital St Antoine, Paris, , France
Hôpital Cochin, Paris, , France
University Hospital, Poitiers, , France
CHRU, Rennes, , France
ICANS, Strasbourg, , France
CHU, Toulouse, , France
CHRU Bretonneau, Tours, , France
Name: Cyrille Touzeau
Affiliation: Nantes University Hospital
Role: PRINCIPAL_INVESTIGATOR